| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥8.6B | ¥8.5B | +1.3% |
| Operating Income | ¥0.6B | ¥-0.6B | +195.2% |
| Ordinary Income | ¥0.6B | ¥-0.6B | +198.3% |
| Net Income | ¥0.3B | ¥-0.5B | +173.9% |
| ROE | 0.6% | -0.8% | - |
FY2026 Q1 results: Revenue 860 million yen (YoY +1.3%), Operating Income 59 million yen (YoY +195.2%), Ordinary Income 59 million yen (YoY +198.3%), Net Income 34 million yen (YoY +173.9%). The company achieved a turnaround to profitability from prior year losses. Gross profit margin remained high at 59.2% with gross profit of 509 million yen. SG&A expenses decreased to 450 million yen (52.3% of revenue) from 528 million yen in the prior period, driving the operating profit improvement. The company maintains a single segment structure in regenerative medicine-related business. Non-operating income and expenses were minimal at 4 million yen and 4 million yen respectively. Extraordinary loss of 12 million yen was recorded, primarily from impairment losses, while extraordinary income of 3 million yen included reversal of subscription rights. The profitability recovery occurred despite essentially flat revenue growth, indicating improved operating leverage through cost management.
Revenue increased marginally by 1.3% to 860 million yen, representing near-flat top-line performance. The company operates solely in the regenerative medicine-related business segment with no diversification. Cost of sales decreased to 351 million yen from 383 million yen YoY, improving gross profit to 509 million yen (gross margin 59.2%) from 466 million yen (54.9%) in the prior period. This 4.3 percentage point gross margin expansion reflects improved production efficiency or pricing power. The key profit driver was SG&A expense reduction of 78 million yen (down 14.8% YoY) to 450 million yen, bringing the SG&A ratio down to 52.3% from 62.2%. This significant operating expense discipline transformed a 62 million yen operating loss into a 59 million yen operating profit. Non-operating items were minimal, with non-operating income of 4 million yen and non-operating expenses of 4 million yen, resulting in ordinary income closely aligned with operating income at 59 million yen. Extraordinary items included impairment loss of 12 million yen as a non-recurring factor, offset partially by 3 million yen in gains from reversal of subscription rights. After tax expenses of 17 million yen (effective tax rate 34%), net income reached 34 million yen versus a 45 million yen loss in the prior period. The profit turnaround follows a "revenue stable/profit up" pattern, driven primarily by gross margin expansion and SG&A cost control rather than top-line growth. The sustainability of this profit recovery depends on whether the cost reductions represent structural improvements or temporary measures, given the full-year forecast still projects an operating loss of 170 million yen.
[Profitability] ROE of 0.6% represents a significant improvement from negative territory in the prior period but remains extremely low, reflecting limited return generation on the 5.95 billion yen equity base. Operating margin of 6.9% improved substantially from negative 7.3% YoY, demonstrating operational recovery. Gross profit margin of 59.2% expanded 4.3 percentage points from 54.9%, indicating strong pricing power or cost management in the core regenerative medicine business. However, the net profit margin of 3.9% remains modest despite the turnaround. [Cash Quality] Cash and deposits of 4.63 billion yen represent 67.1% of total assets, providing exceptional liquidity strength. Short-term debt coverage stands at approximately 121 times (cash/current liabilities), indicating robust ability to meet near-term obligations. [Investment Efficiency] Total asset turnover of 0.125 (annualized basis) remains very low, reflecting the capital-light nature of assets dominated by cash holdings rather than productive operating assets. Working capital management shows room for improvement with trade receivables at 291 million yen and inventories totaling 264 million yen (finished goods 77 million yen, work in process 42 million yen, raw materials 144 million yen). [Financial Health] Equity ratio of 86.3% indicates an extremely conservative capital structure with minimal leverage. Current ratio of approximately 1,395% (5.34 billion yen current assets / 383 million yen current liabilities) demonstrates exceptionally strong short-term solvency. Debt-to-equity ratio of 0.16 reflects negligible financial leverage. The balance sheet shows 6.89 billion yen in total assets against only 942 million yen in liabilities. Intangible assets increased significantly to 136 million yen from 56 million yen YoY, potentially reflecting development investments requiring monitoring for impairment risk.
Cash and deposits decreased by 87 million yen to 4.63 billion yen from 4.71 billion yen YoY, representing a 1.8% decline despite the return to profitability. Total assets decreased by 131 million yen to 6.89 billion yen, driven by reductions in current assets which fell to 5.34 billion yen from 5.49 billion yen. Within working capital, trade receivables decreased by 47 million yen to 291 million yen, improving collection efficiency. Inventories declined by 12 million yen to 264 million yen, showing marginally better inventory management. On the liability side, current liabilities decreased to 383 million yen from 443 million yen, including a reduction in income taxes payable from 28 million yen to 15 million yen and provision for bonuses declining from 63 million yen to 29 million yen, suggesting lower accrued compensation. Trade payables increased slightly by 5 million yen to 67 million yen. Non-current liabilities decreased marginally to 559 million yen from 564 million yen, primarily asset retirement obligations of 302 million yen. The balance sheet changes indicate modest cash consumption despite positive net income, likely reflecting timing differences in working capital and expense accruals. Property, plant and equipment declined to 937 million yen from 989 million yen, suggesting depreciation exceeded capital expenditures. Intangible assets increased substantially by 80 million yen to 136 million yen, representing significant investment in development or licensing activities. The cash coverage ratio remains exceptionally strong at over 12 times current liabilities, maintaining substantial financial flexibility despite the modest cash decline.
Ordinary income of 59 million yen versus operating income of 59 million yen shows virtually no contribution from non-operating items, indicating core business operations drove the profitability recovery. Non-operating income totaled 4 million yen, primarily miscellaneous income of 2 million yen, while non-operating expenses of 4 million yen included minimal interest expense of 0.3 million yen. The near-zero net non-operating impact represents less than 0.5% of revenue, demonstrating that earnings quality is primarily based on operating performance rather than financial engineering or extraordinary items. Extraordinary items showed a net loss of 9 million yen, comprising impairment losses of 12 million yen partially offset by gains on asset sales of 2 million yen and reversal of subscription rights of 3 million yen. The impairment loss represents a non-recurring factor that should be excluded when assessing normalized profitability. Tax expense of 17 million yen on pretax income of 51 million yen represents an effective tax rate of approximately 34%, which is reasonable and suggests no significant deferred tax benefits artificially boosting net income. The alignment between operating income and ordinary income, combined with minimal reliance on non-operating gains, indicates solid earnings quality from core operations. However, the significant SG&A reduction driving the profit turnaround warrants monitoring to ensure sustainability. Without access to operating cash flow data for the quarter, a full accruals assessment cannot be performed, though the balance sheet shows working capital management improvements that suggest cash generation potential.
Full-year forecast projects revenue of 3.42 billion yen (YoY decline of 7.9%), operating loss of 170 million yen, ordinary loss of 164 million yen, and net loss of 136 million yen with EPS of negative 6.90 yen. Q1 revenue of 860 million yen represents 25.1% progress toward the annual target, in line with a standard quarterly run rate. However, Q1 operating profit of 59 million yen contrasts sharply with the full-year operating loss forecast of 170 million yen, implying the company expects significant deterioration in subsequent quarters totaling approximately 229 million yen in combined operating losses for Q2-Q4. This guidance assumes substantial negative seasonality or planned investments in later periods. No forecast revision was made this quarter despite the Q1 profit turnaround, suggesting management maintains a conservative outlook. The annual revenue forecast implies a significant decline from prior year levels, indicating expected business headwinds or strategic repositioning. The divergence between Q1 profitability and full-year loss guidance represents a critical monitoring point, as it suggests either temporary cost deferrals in Q1, expected revenue decline in later quarters, or planned stepped-up investments. Dividend forecast remains at zero yen, consistent with the projected annual loss and conservative capital allocation during the business transition period.
Single segment concentration risk in regenerative medicine-related business exposes the company to sector-specific regulatory, technological, and market adoption challenges without diversification benefits. With total assets of 6.89 billion yen entirely dependent on this single business line, any adverse developments in regenerative medicine commercialization, reimbursement policies, or competitive dynamics would directly impact the entire enterprise. Asset efficiency and capital deployment risk evidenced by exceptionally low ROE of 0.6% and total asset turnover of 0.125, with 67% of assets held as cash earning minimal returns. Despite strong financial health, the company has yet to demonstrate effective deployment of its 4.63 billion yen cash position into value-creating investments, raising questions about strategic capital allocation. Intangible assets increased 141% to 136 million yen, suggesting increased development investments or licensing activities that carry execution risk and potential impairment if commercial milestones are not achieved. Operating leverage sustainability risk from the divergence between Q1 profitability (59 million yen operating income) and full-year loss guidance (170 million yen operating loss), implying significant quarterly volatility or planned investments that may pressure margins. The SG&A reduction of 78 million yen driving Q1 profit recovery requires validation as a sustainable structural improvement rather than temporary cost deferral.
[Industry Position] (Reference - Proprietary Analysis)
Cellsource operates in the regenerative medicine sector with highly specialized business characteristics. The company's operating margin of 6.9% and net profit margin of 3.9% reflect early-stage commercialization dynamics typical of regenerative medicine businesses, which often experience extended periods of investment and regulatory development before achieving stable profitability. The company's equity ratio of 86.3% significantly exceeds typical biotech/medtech industry levels of 60-70%, indicating exceptionally conservative financing with minimal leverage utilization. ROE of 0.6% falls well below regenerative medicine sector benchmarks, which typically range from 5-15% for established players, reflecting the company's challenge in generating returns on its substantial equity base. The cash-heavy balance sheet with 67% of assets in cash and deposits is characteristic of pre-commercial or early commercial-stage life science companies maintaining financial flexibility for R&D and regulatory activities, though it also indicates underutilized capital. Asset turnover of 0.125 is low even by capital-light biotech standards, suggesting the company is in a transitional phase between development and commercial scaling. The single-segment focus is common among specialized regenerative medicine companies but concentrates business risk. Industry data suggests that companies successfully transitioning from development to commercial operations typically show improving operating margins (moving from negative to 10-15% range) and accelerating revenue growth (15-30% annually), benchmarks against which Cellsource's flat revenue growth and projected full-year losses indicate ongoing commercialization challenges.
(Industry: Regenerative Medicine/Biotechnology sector characteristics, Comparison: Early commercial-stage biotech financial profiles, Source: Proprietary analysis)
Profitability inflection achieved with Q1 turnaround to operating profit of 59 million yen from 62 million yen loss, driven by 4.3 percentage point gross margin expansion to 59.2% and 14.8% SG&A reduction, though sustainability remains uncertain given full-year loss guidance. This represents a critical monitoring point for whether operational improvements are structural or temporary. Exceptional financial safety with equity ratio of 86.3%, cash holdings of 4.63 billion yen covering current liabilities 12 times over, and debt-to-equity ratio of only 0.16, providing substantial runway for continued business development without near-term financing pressure. However, this financial strength contrasts sharply with ROE of 0.6% and asset turnover of 0.125, indicating significant underutilization of capital resources. Intangible asset investment acceleration with 141% increase to 136 million yen suggests intensified development or partnership activities that could drive future growth but also introduce execution risk and potential impairment exposure requiring close monitoring of commercialization milestones and asset quality.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.